Reading time: 2 – 3 minutes
Bayer HealthCare has entered into a master collaboration agreement with the diagnostic company Sysmex Inostics GmbH for the development of companion diagnostics for targeted cancer therapies. The innovative blood-based companion diagnostic solutions offered by Sysmex Inostics will complement anti-cancer agents developed by Bayer.
“We are excited to collaborate with the team at Sysmex Inostics on the development of blood-based companion diagnostic tests for our novel targeted therapies in oncology,” said Prof. Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of Bayer HealthCare. “Blood-based DNA tests provide diagnostic options for cancer patients without tumor biopsies being necessary. With this collaboration, we continue to strengthen our engagement in the field of personalized medicine with the aim of developing innovative therapies for cancer patients.”
Companion diagnostic tests are designed to analyze specific molecular charateristics of a patient’s tumor to help guide treatment decisions. The tests provide evidence which patients are more likely to respond to a particular anti-cancer agent. Under the master collaboration agreement, Sysmex Inostics will develop blood-based diagnostic tests based on its BEAMing technology. Sysmex Inostics BEAMing tests enable a very sensitive analysis of circulating tumor DNA shed into the blood stream from tumors which provides a non-invasive alternative to tumor biopsy to analyze the mutational status of a patient’s tumor. The non-invasive diagnostic blood tests allow the selection of an appropriate therapeutic agent without the need of further surgeries or tumor biopsies. Moreover, blood-based diagnostic DNA tests can be performed on patients where no tumor tissue is available.
“We are pleased to partner with Bayer HealthCare, a global company with an extensive drug development expertise and a broadening oncology franchise, to advance new targeted therapies for cancer patients,” said Frank Diehl, CSO of Sysmex Inostics. “With our innovative technology for blood-based companion diagnostics we will open up new possibilities in personalized medicine together with Bayer.”
An initial blood-based companion diagnostic test will be applied in clinical trials to select patients more likely to achieve a clinical benefit to an investigational anti-cancer agent developed by Bayer HealthCare. Moreover, the partnership provides a framework for further collaboration projects to develop molecular blood-based diagnostic tests in support of additional targeted cancer therapies. Financial terms of the agreement were not disclosed.
Source: Bayer HealthCare